Last reviewed 2026-06-03 · How we verify

Rescue Antacid

POZEN · Phase 3 active Small molecule

Rescue Antacid is a Antacid Small molecule drug developed by POZEN. It is currently in Phase 3 development for Heartburn and acid indigestion relief.

Rescue Antacid neutralizes stomach acid to provide rapid relief from heartburn and acid indigestion.

Rescue Antacid neutralizes stomach acid to provide rapid relief from heartburn and acid indigestion. Used for Heartburn and acid indigestion relief.

Likelihood of approval

58.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Rescue Antacid
Sponsor	POZEN
Drug class	Antacid
Modality	Small molecule
Therapeutic area	Gastroenterology
Phase	Phase 3

Mechanism of action

The drug works by buffering excess gastric acid, raising the pH of stomach contents to reduce irritation of the esophageal lining. This provides symptomatic relief of acid reflux and heartburn, typically within minutes of administration.

Approved indications

Heartburn and acid indigestion relief

Common side effects

Constipation
Diarrhea
Nausea

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Rescue Antacid CI brief — competitive landscape report
Rescue Antacid updates RSS · CI watch RSS
POZEN portfolio CI

Frequently asked questions about Rescue Antacid

What is Rescue Antacid?

Rescue Antacid is a Antacid drug developed by POZEN, indicated for Heartburn and acid indigestion relief.

How does Rescue Antacid work?

Rescue Antacid neutralizes stomach acid to provide rapid relief from heartburn and acid indigestion.

What is Rescue Antacid used for?

Rescue Antacid is indicated for Heartburn and acid indigestion relief.

Who makes Rescue Antacid?

Rescue Antacid is developed by POZEN (see full POZEN pipeline at /company/pozen).

What drug class is Rescue Antacid in?

Rescue Antacid belongs to the Antacid class. See all Antacid drugs at /class/antacid.

What development phase is Rescue Antacid in?

Rescue Antacid is in Phase 3.

What are the side effects of Rescue Antacid?

Common side effects of Rescue Antacid include Constipation, Diarrhea, Nausea.

Drug class: All Antacid drugs
Manufacturer: POZEN — full pipeline
Therapeutic area: All drugs in Gastroenterology
Indication: Drugs for Heartburn and acid indigestion relief

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing